Key result
Ticagrelor reduces recurrent major cardiovascular events compared with clopidogrel in patients with coronary artery disease, but is counterbalanced by an increased risk of major bleeding.
Why the study?
Does ticagrelor reduce recurrent major cardiovascular events compared with clopidogrel in patients with coronary artery disease?
Does ticagrelor reduce recurrent major cardiovascular events compared with clopidogrel in patients with coronary artery disease?
Ticagrelor is a potent P2Y12 inhibitor that effectively reduces recurrent cardiovascular events in CAD but carries an increased risk of major bleeding, particularly in stable CAD.
May support ticagrelor in CAD; leaves open optimal regimens and patient selection in current practice.
Ticagrelor is a potent and orally active P2Y12 inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and pharmacodynamics of ticagrelor result in more rapid and effective inhibition of platelet activation compared with other P2Y12 inhibitors. This has resulted in a reduction in recurrent major cardiovascular events in initial randomized controls trials comparing ticagrelor with clopidogrel. More recently, clinical trials have investigated the use of ticagrelor in patients with stable coronary artery disease and a high residual risk of coronary thrombotic events. In patients with stable coronary artery disease, the potent antiplatelet effect of ticagrelor is counterbalanced by an increased risk of major bleeding. Further research is ongoing to determine the optimal duration of ticagrelor therapy.
No takes yet. Share an insight, caveat, or question.
Loganath et al. (2020) conducted a review in Coronary artery disease. Ticagrelor vs. Clopidogrel and other P2Y12 inhibitors was evaluated. Ticagrelor reduces recurrent major cardiovascular events compared with clopidogrel in patients with coronary artery disease, but is counterbalanced by an increased risk of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Coronary artery diseaseMore from Future Cardiology